Postinterferon α-fetoprotein elevation and risk of hepatocellular carcinoma development after sustained virological response: Cause or results?

Hepatology

Volumn 60, Issue 2, 2014, Pages 762-763

  Toyoda, Hidenori ^a   Kumada, Takashi ^a   Tada, Toshifumi ^a  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; INTERFERON;

ALPHA FETOPROTEIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CANCER RISK; FOLLOW UP; FUCOSYLATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; TUMOR VOLUME; VIRAL CLEARANCE;

ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE;

EID: 84904735207     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27064     Document Type: Article

References (3)

1. Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, et al. α-Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013;58:1253-1262.
2. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89:259-266.
3. Kumada T, Toyoda H, Tada T, Kiruyama S, Tanikawa M, Hisanaga Y, et al. High-sensitivity Lens culinaris agglutinin-reactive alpha-protein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol [Epub ahead of print].